Brief: Clearside Biomedical Announces Enrollment Of Multiple Participants In Odyssey Phase 2B Clinical Trial Of Cls-Ax In Wet AMD
17/07/2023 12:12
July 17 (Reuters) - Clearside Biomedical Inc CLSD.O :
* CLEARSIDE BIOMEDICAL ANNOUNCES ENROLLMENT OF MULTIPLE
PARTICIPANTS IN ITS ODYSSEY PHASE 2B CLINICAL TRIAL OF CLS-AX
(AXITINIB INJECTABLE SUSPENSION) IN WET AMD
* CLEARSIDE BIOMEDICAL INC - TRIAL PROGRESSING WITH TOPLINE
RESULTS EXPECTED IN Q3 2024
* CLEARSIDE BIOMEDICAL INC - TRIAL PROGRESSING WITH TOPLINE
RESULTS EXPECTED IN Q3 2024
Source text for Eikon: ID:nGNX4DcN1k
Further company coverage: CLSD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearside Biomedical,
See all newsBrief: Clearside Biomedical Completes Financial Restructuring And Emerges From Chapter 11 With Steel Partners As Plan Sponsor
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Clearside Biomedical plunges after filing for Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials